Literature DB >> 28338082

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

G Montalban-Bravo, X Huang, K Naqvi, E Jabbour, G Borthakur, C D DiNardo, N Pemmaraju, J Cortes, S Verstovsek, T Kadia, N Daver, W Wierda, Y Alvarado, M Konopleva, F Ravandi, Z Estrov, N Jain, A Alfonso, M Brandt, T Sneed, H C Chen, H Yang, C Bueso-Ramos, S Pierce, E Estey, Z Bohannan, H M Kantarjian, G Garcia-Manero.   

Abstract

This corrects the article DOI: 10.1038/leu.2016.303.

Entities:  

Year:  2017        PMID： 28338082     DOI： 10.1038/leu.2017.85

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  3 in total

Review 1.  Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities.

Authors:  Abhishek A Mangaonkar; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

2.  Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis.

Authors:  Luis Enrique Colunga-Lozano; Fernando Kenji Nampo; Arnav Agarwal; Pinkal Desai; Mark Litzow; Mikkael A Sekeres; Gordon H Guyatt; Romina Brignardello-Petersen
Journal:  PLoS One       Date:  2022-02-02       Impact factor: 3.240

3.  Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.

Authors:  Abby Statler; Megan Othus; Harry P Erba; Thomas R Chauncey; Jerald P Radich; Steven Coutre; Anjali Advani; Sucha Nand; Farhad Ravandi; Sudipto Mukherjee; Mikkael A Sekeres
Journal:  Blood       Date:  2018-04-04       Impact factor: 25.476
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.